Search Results: Genentech v. Amgen (bevacizumab)

Amgen’s Motion to Dismiss Genentech’s Complaint in the Delaware Mvasi Litigation

As we previously reported, Genentech has filed two pending cases (Case Nos. 1:17-cv-01407 and 1:17-cv-01471) in the District of Delaware related to Amgen’s proposed Mvasi (bevacizumab-awwb), a biosimilar of Genentech’s Avastin.  On December 6, 2017, Genentech filed a sealed amended and supplemental complaint in Case No. 1:17-cv-01407, and on December 13, Genentech filed a redacted version.  Last month Amgen…

Read More

Genentech Files A Complaint Against Amgen in Delaware Regarding MVASI® (bevacizumab-awwb)

We previously reported that on October 6, 2017, Amgen filed a declaratory judgment action against Genentech regarding Amgen’s recently approved biosimilar of Avastin® (bevacizumab-awwb). On the same day, Genentech filed a complaint in the District of Delaware, Civil Action No. 1:17cv1407.  While the complaint was filed under seal, according to a motion to transfer…

Read More